Navigation Links
Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology
Date:10/4/2010

dates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and

Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. FDA for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA approved labeling for the products, and not the information discussed in this news release.CONTACT: AmgenAshleigh Koss: +1 (805) 313-6151 (U.S. media)Carrie Deverell: +41 41 3690 308 (E.U. media)Sabrina Paiva: +1 (905) 285-3145 (Canada media)Arvind Sood: +1 (805) 447-1060 (investors)(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGE
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
2. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
3. Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial
4. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
5. Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
8. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
9. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
10. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Israel Biomedical Sensors Market - Growth, Trends & Forecasts ... The Israel Biomedical Sensors market is estimated at $0.19 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)... Aug. 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... the 30-day review period following the filing of ... indications with the U.S. Food and Drug Administration ... active. Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... LabStyle Innovations Corp. (OTCQB: DRIO), developer ... it recently closed a round of funding totaling ... support the global rollout and initial U.S. commercial ... management solution that includes novel software applications combined ... device, and for working capital purposes. The Dario ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... There’s a ... Minerva is the first commercially available new FDA approved system in the last ... rate of 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... , , , , , The programming example given below shows a , ... , , , , , ... Explanation, , , ... Temperature control for the , block., ...
... , , , , , ... Variable heating and cooling rates, which can be programmed as desired with , ... aligned to the temperature. , , ... it may be necessary to heat , up carefully after annealing. , ...
... , , , , , , ... only) , , ... gradient may be programmed , with ... The most common application is the determination of the optimal annealing , ...
Cached Biology Technology:Title 2
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... Korea Advanced Institute of Science and Technology (KAIST) and ... on February 20th, 2013 the Master Research and Collaboration ... development of carbon management between the two entities. ... of the Memorandum of Understanding (MOU) between KAIST and ...
... orthopaedists and a wide number of specialists concerned with ... Asia-Pacific,s key clinical bone event in 2013. The ... cooperation with the Hong Kong Osteoporosis Foundation and the ... December 12-15, 2013 in Hong Kong. More than ...
... (February 26th, 2013) Canadian agriculture is faced ... risks and uncertainties. An expert panel convened by ... water and land resources in Canada can be ... effective land and water management strategies, adopting effective ...
Cached Biology News:Launched the Saudi Aramco-KAIST CO2 Management Center in Korea 2Report: 'Water and Agriculture in Canada: Towards Sustainable Management of Water Resources' 2
ready-to-use solution...
... MS/MS analysis & visualization ... across multiple samples. Combine ... for increased confidence. Get ... information from your MS/MS ...
... Synthetic peptide derived from the N-terminal ... dog and orangutang occludin proteins. ... protein. Reactivity: Human (positive controls: ... rat mouse dog and orangutang is ...
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: